Abstract
Platinum-based doublets are the cornerstone of treatment in advanced non-small-cell lung cancer (NSCLC) and often include vinorelbine or taxanes. A predictive biomarker is greatly needed to select chemotherapy-sensitive patients for these microtubule-interfering agents. Class III β-tubulin (TUBB3) has been shown of value in NSCLC, but evidence is not uniform. Accordingly, we explored the predictive role of TUBB3 in advanced NSCLC.
| Original language | English |
|---|---|
| Journal | Clinical Cancer Research |
| Volume | 17 |
| Issue number | 15 |
| Pages (from-to) | 5205-14 |
| Number of pages | 10 |
| ISSN | 1078-0432 |
| DOIs | |
| Publication status | Published - 2011 |
Keywords
- Adenocarcinoma
- Adolescent
- Adult
- Aged
- Antineoplastic Agents
- Carcinoma, Non-Small-Cell Lung
- Disease-Free Survival
- Female
- Humans
- Lung Neoplasms
- Male
- Middle Aged
- Paclitaxel
- Prognosis
- Survival Rate
- Treatment Outcome
- Tubulin
- Tumor Markers, Biological
- Vinblastine
Fingerprint
Dive into the research topics of 'Class III β-tubulin in advanced NSCLC of adenocarcinoma subtype predicts superior outcome in a randomized trial'. Together they form a unique fingerprint.Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS